psilocybin | 60480-02-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: psilocybin
• 英文别名: Ethocybin；[3-[2-(diethylamino)ethyl]-1H-indol-4-yl] dihydrogen phosphate
• CAS: 60480-02-6
• 化学式: C₁₄H₂₁N₂O₄P
• 分子量: 312.305
• InChiKey: AAVKQQUBPHSCML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.9
• 重原子数：
  21
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  85.8
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 甲醇 、 aluminum oxide 、 palladium/alumina 作用下， 生成 psilocybin
  参考文献：
  名称：

  抑菌素和抑菌素。2.合成论

  摘要：

  对天然精神药物psilocybin（I）和psilocin（11）的分子结构进行了各种修饰，以了解这组物质的结构与精神作用之间的关系。描述了四个异构体羟基葡糖胺的I和II的位置异构体的合成和性质，其中I和II在5、6或7位具有磷酰氧基或羟基，以及一系列其他的4-羟基吲哚衍生物其中II的结构被系统地修饰，即在ω-氮处具有其他取代的psilocin衍生物；在吲哚氮上取代的II的衍生物；在侧链上具有一个另外的亚甲基或具有甲基取代的或羟基化的侧链的psilocin衍生物；II的一些衍生物的磷酸酯；II与有机碳酸和磺酸，甲基氨基甲酸酯和硫酸的酯；psilocin的位置异构体，其二甲基氨基乙基侧链位于1或2位。

  DOI：

  10.1002/hlca.19590420638

文献信息

• COMPOSITIONS COMPRISING A PSILOCYBIN DERIVATIVE AND A CANNABINOID
  申请人：CaaMTech, LLC

  公开号：US20190142851A1

  公开（公告）日：2019-05-16

  This disclosure pertains to new compositions and methods comprising a psilocybin derivative. In one embodiment, the compositions disclosed herein are used for a method of regulating a neurotransmitter receptor, e.g., a serotonin receptor. In one embodiment, the compositions disclosed herein comprise purified compounds, e.g., a purified psilocybin derivative, a purified cannabinoid, or purified terpene.
• COMPOSITIONS COMPRISING A SEROTONERGIC TRYPTAMINE COMPOUND
  申请人：CAAMTECH, INC.

  公开号：US20210346346A1

  公开（公告）日：2021-11-11

  Disclosed herein are compositions comprising a serotonergic tryptamine compound, combinations thereof, and methods of using them for treating and preventing a variety of human conditions. In one embodiment, disclosed herein are new compositions and methods which comprise a therapeutically effective amount of a first purified psilocybin derivative and a therapeutically effective amount of a second compound. The second compound is selected from the group consisting of a second purified psilocybin derivative, a purified terpene, a serotonergic drug, an adrenergic drug, a dopaminergic drug, a purified erinacine, and a purified hericenone.
• [EN] COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL CONDITIONS<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE PATHOLOGIES NEUROLOGIQUES
  申请人：[en]WESANA HEALTH INC.

  公开号：WO2022115796A1

  公开（公告）日：2022-06-02

  As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating neurological conditions (e.g., traumatic brain injury or TBI), or symptoms thereof (e.g., anxiety or depression), with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., TBI), or symptoms thereof (e.g., anxiety or depression).
• [EN] COMPOSITIONS AND METHODS FOR TREATING MIGRAINE<br/>[FR] COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE LA MIGRAINE
  申请人：[en]WESANA HEALTH INC.

  公开号：WO2022115798A2

  公开（公告）日：2022-06-02

  As described below, the present disclosure features compositions containing a cannabidiol (CBD) and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features methods for treating or preventing migraine, or symptoms thereof, with a cannabidiol and/or psilocybin, optionally in combination with a mushroom blend. The present disclosure also features compositions and methods of using psilocybin in combination with a neurotransmitter activity modulator for the treatment of neurological conditions (e.g., migraine), or symptoms thereof (e.g., anxiety or depression).
• [EN] TRANSDERMAL SYSTEM, FORMULATION, AND METHOD FOR THE THERAPEUTIC ADMINISTRATION OF A PSYCHEDELIC AGENT<br/>[FR] SYSTÈME TRANSDERMIQUE, FORMULATION ET MÉTHODE D'ADMINISTRATION THÉRAPEUTIQUE D'UN AGENT PSYCHÉDÉLIQUE
  申请人：[en]MYCRODOSE THERAPEUTICS INC.

  公开号：WO2022212789A1

  公开（公告）日：2022-10-06

  A drug delivery system is provided for transdermally administering a psychedelic active agent to a subject to provide continuous microdose plasma levels of the active agent or a metabolite thereof during an extended drug delivery time period. The transdermal drug delivery system comprises a drug reservoir that houses a formulation containing the active agent, a combination of a solubilizer-type permeation enhancer and a plasticizer-type permeation enhancer, and a pH stabilizing agent. The pH stabilizing agent brings the pH of the formulation, at the system-skin interface, and/or within the skin as the active agent is transported across the skin from the skin surface to the bloodstream, to within 25% of the pKa of the active agent. Formulations and methods of use are also provided.